文献速递浆细胞疾病

基于二代测序的MRD定量分层对初治多发性骨髓瘤诱导治疗后早期进展的预测价值

[Predictive value of next-generation sequencing-based measurable residual disease quantitative stratification for early disease progression in newly diagnosed multiple myeloma after induction therapy].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

该回顾性队列研究纳入408例接受VRD诱导联合自体造血干细胞移植的初治多发性骨髓瘤患者,于4疗程诱导后、移植前以灵敏度10^-6的NGS检测MRD并分为超深度阴性、低负荷阳性及高负荷残留三组。结果显示MRD水平为独立预后因素,超深度阴性组较高负荷残留组疾病进展风险降低86%。

要点

  • 4疗程VRD诱导后总反应率96.8%,完全缓解及以上48.3%。
  • 超深度阴性组24个月累积进展发生率1.2%,高负荷残留组23.2%。
  • MRD水平为独立预后因素,高负荷残留组进展风险显著高于超深度阴性组。

核心结论

  • 基于NGS的MRD定量分层对诱导治疗后NDMM患者早期疾病进展有独立预测价值。

研究设计与样本

  • 回顾性队列研究,纳入2019至2024年苏州大学附属第一医院408例接受VRD诱导联合auto-HSCT的NDMM患者。
  • 于4个疗程诱导结束后、auto-HSCT前采集骨髓,采用灵敏度10^-6的NGS技术检测MRD。
  • 按MRD负荷分为超深度阴性组(<10^-6,90例)、低负荷阳性组(≥10^-6且≤10^-3,142例)和高负荷残留组(>10^-3,176例)。

主要发现

  • 4个疗程VRD诱导后总反应率96.8%(395/408),完全缓解及以上197例(48.3%)。
  • 超深度阴性组、低负荷阳性组、高负荷残留组del(17p)阳性率分别为4.4%、15.5%、10.8%(P=0.030)。
  • 三组t(4;14)阳性率分别为13.3%、19.0%、28.4%(P=0.021),以高负荷残留组最高。
  • 超深度阴性组疾病进展风险较高负荷残留组降低86%(HR=0.14,95%CI:0.08~0.26,P<0.001)。
  • 三组24个月累积进展发生率分别为1.2%(95%CI:0.1%~5.9%)、8.3%(95%CI:4.4%~13.9%)、23.2%(95%CI:17.2%~29.7%)。

关键数值与推荐

  • 以高负荷残留组为参照,超深度阴性组疾病进展风险sHR=0.15(95%CI:0.08~0.31),低负荷阳性组sHR=0.33(95%CI:0.22~0.50),P值均<0.001。
  • 超深度阴性组疾病进展风险较低负荷阳性组亦显著降低(sHR=0.48,95%CI:0.24~0.94,P=0.032)。
  • 多因素分析显示MRD水平为独立预后因素,高负荷残留组疾病进展风险较超深度阴性组显著升高(sHR=6.65,95%CI:3.58~12.33,P<0.001)。

临床怎么用

  • 对NDMM患者诱导治疗后、auto-HSCT前可采用灵敏度10^-6的NGS检测MRD并进行定量分层。
  • MRD超深度阴性提示早期进展风险低,高负荷残留提示进展风险高,可辅助预后评估。
  • MRD定量分层结果可作为独立预后因素纳入临床决策参考。

局限性

  • 本研究为单中心回顾性队列研究。
  • 仅纳入接受VRD诱导联合auto-HSCT的患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the predictive value of next-generation sequencing (NGS) -based quantitative minimal residual disease (MRD) stratification for early disease progression in patients newly diagnosed with multiple myeloma (NDMM) after induction therapy. Methods: This retrospective cohort study analyzed the clinical data of 408 patients with NDMM admitted to the Department of Hematology, the First Affiliated Hospital of Soochow University between 2019 and 2024, who received the bortezomib + lenalidomide + dexamethasone (VRD) regimen induction therapy combined with autologous hematopoietic stem cell transplantation (auto-HSCT). Bone marrow samples were collected after 4 cycles of induction therapy and before auto-HSCT, and MRD was detected by NGS technology with a sensitivity of 10-6. Patients were divided into the ultra-deep negative group (<10(-6)), low-load positive group (≥10(-6) and ≤10(-3)), and high-load residual group (>10(-3)) according to MRD burden, and the clinical characteristics and prognosis of each group were compared. Results: After cycles of VRD induction therapy, the overall response rate was 96.8% (395/408), and 197 patients (48.3%) achieved complete remission or better. The positive rates of del (17p) were 4.4%, 15.5%, and 10.8%, respectively (P=0.030) and the positive rates of t (4;14) were 13.3%, 19.0%, and 28.4% (P=0.021) in the ultra-deep negative group (90 patients), low-load positive group (142 patients), and high-load residual group (176 patients), respectively, with the highest rate observed in the high-load residual group. The risk of disease progression in the ultra-deep negative group was reduced by 86% compared with the high-load residual group (HR=0.14, 95%CI: 0.08 - 0.26, P<0.001). The 24-month cumulative incidence of progression (CIF) in the ultra-deep negative group, low-load positive group, and high-load residual group was 1.2% (95% CI: 0.1% - 5.9%), 8.3% (95% CI: 4.4% - 13.9%), and 23.2% (95% CI: 17.2% - 29.7%), respectively. Using the high-load residual group as reference, the risk of disease progression was significantly reduced in both the ultra-deep negative group (sHR = 0.15, 95% CI: 0.08 - 0.31) and the low-load positive group (sHR=0.33, 95% CI: 0.22 - 0.50) (both P<0.001). The risk of disease progression in the ultra-deep negative group was also significantly lower than that in the low-load positive group (sHR=0.48, 95% CI: 0.24 - 0.94, P=0.032). Multivariate analysis revealed that the MRD level was an independent prognostic factor, and the risk of disease progression in the high-load residual group was significantly higher than that in the ultra-deep negative group (sHR=6.65, 95% CI: 3.58 - 12.33, P<0.001) . Conclusion: NGS-based quantitative MRD stratification has independent predictive value for early disease progression in patients with NDMM after induction therapy. 目的: 评估基于二代测序(NGS)的微小残留病(MRD)定量分层对诱导治疗后初治多发性骨髓瘤(NDMM)患者早期疾病进展的预测价值。 方法: 本回顾性队列研究分析了2019年至2024年苏州大学附属第一医院血液科收治的408例接受VRD方案(硼替佐米+来那度胺+地塞米松)诱导治疗联合自体造血干细胞移植(auto-HSCT)的NDMM患者的临床资料。于4个疗程诱导结束后、auto-HSCT前采集患者的骨髓标本,采用灵敏度10(-6)的NGS技术检测MRD。按MRD负荷将患者分为超深度阴性组(<10(-6))、低负荷阳性组(≥10(-6)且≤10(-3))及高负荷残留组(>10(-3)),比较各组患者的临床特征及预后。 结果: 4个疗程VRD方案诱导治疗后患者总反应率为96.8%(395/408),疗效达完全缓解及以上197例(48.3%)。超深度阴性组(90例)、低负荷阳性组(142例)、高负荷残留组(176例)del(17p)阳性率分别为4.4%、15.5%、10.8%(P=0.030);t(4;14)阳性率分别为13.3%、19.0%、28.4%(P=0.021),以高负荷残留组最高。超深度阴性组的疾病进展风险较高负荷残留组降低86%(HR=0.14,95%CI:0.08~0.26,P<0.001)。超深度阴性组、低负荷阳性组及高负荷残留组24个月累积进展发生率(CIF)分别为1.2%(95% CI:0.1%~5.9%)、8.3%(95% CI:4.4%~13.9%)、23.2%(95% CI:17.2%~29.7%)。以高负荷残留组为参照,超深度阴性组(sHR=0.15,95%CI:0.08~0.31)及低负荷阳性组(sHR=0.33,95%CI:0.22~0.50)疾病进展风险均显著降低(P值均<0.001);超深度阴性组疾病进展风险较低负荷阳性组亦显著降低(sHR=0.48,95%CI:0.24~0.94,P=0.032)。多因素分析显示,MRD水平为独立预后因素,高负荷残留组的疾病进展风险较超深度阴性组显著升高(sHR=6.65,95%CI:3.58~12.33,P<0.001)。 结论: 基于NGS的MRD定量分层对诱导治疗后NDMM患者早期疾病进展有独立预测价值。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Peng YH, Zhou X, Yan S, et al. [Predictive value of next-generation sequencing-based measurable residual disease quantitative stratification for early disease progression in newly diagnosed multiple myeloma after induction therapy]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42706174. doi:10.3760/cma.j.cn121090-20260403-00173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。